Investment analysts at Guggenheim began coverage on shares of Mylan (NASDAQ:MYL) in a research report issued to clients and investors on Tuesday, The Fly reports. The firm set a “buy” rating on the stock.

A number of other brokerages have also issued reports on MYL. Wells Fargo & Company set a $32.00 price objective on Mylan and gave the stock a “hold” rating in a report on Wednesday, October 4th. Morgan Stanley raised their price objective on Mylan from $36.00 to $39.00 and gave the stock an “equal weight” rating in a research note on Friday, October 6th. BidaskClub raised Mylan from a “hold” rating to a “buy” rating in a research note on Friday, October 27th. BMO Capital Markets reissued a “buy” rating and set a $45.00 price objective on shares of Mylan in a research note on Friday, September 29th. Finally, ValuEngine upgraded Mylan from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the stock. Mylan has an average rating of “Buy” and an average target price of $41.49.

Mylan (MYL) opened at $39.49 on Tuesday. The company has a market capitalization of $20,743.99, a PE ratio of 8.23, a P/E/G ratio of 2.12 and a beta of 1.38. Mylan has a 1-year low of $29.39 and a 1-year high of $45.87. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05.

Mylan (NASDAQ:MYL) last issued its quarterly earnings results on Monday, November 6th. The company reported $1.10 EPS for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.10). Mylan had a net margin of 7.28% and a return on equity of 20.63%. The business had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. During the same period in the prior year, the company posted $1.38 EPS. The company’s revenue for the quarter was down 2.3% on a year-over-year basis. equities analysts forecast that Mylan will post 4.56 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Pzena Investment Management LLC grew its position in shares of Mylan by 84.1% during the 3rd quarter. Pzena Investment Management LLC now owns 22,721,384 shares of the company’s stock worth $712,770,000 after purchasing an additional 10,381,697 shares in the last quarter. Vanguard Group Inc. lifted its stake in Mylan by 12.0% in the 2nd quarter. Vanguard Group Inc. now owns 32,880,790 shares of the company’s stock valued at $1,276,432,000 after purchasing an additional 3,531,974 shares during the last quarter. BlackRock Inc. raised its stake in shares of Mylan by 4.5% during the second quarter. BlackRock Inc. now owns 40,574,158 shares of the company’s stock valued at $1,575,089,000 after acquiring an additional 1,751,515 shares during the last quarter. Schroder Investment Management Group raised its stake in shares of Mylan by 161,445.9% during the second quarter. Schroder Investment Management Group now owns 1,731,772 shares of the company’s stock valued at $67,124,000 after acquiring an additional 1,730,700 shares during the last quarter. Finally, Teachers Advisors LLC raised its stake in shares of Mylan by 72.2% during the second quarter. Teachers Advisors LLC now owns 3,346,814 shares of the company’s stock valued at $129,923,000 after acquiring an additional 1,403,273 shares during the last quarter. 75.04% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Mylan (MYL) Now Covered by Guggenheim” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/12/12/mylan-myl-now-covered-by-guggenheim.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

The Fly

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.